| Download | - View final version: Antisense oligonucleotides: absorption, distribution, metabolism, and excretion (PDF, 917 KiB)
|
|---|
| DOI | Resolve DOI: https://doi.org/10.1080/17425255.2021.1992382 |
|---|
| Author | Search for: Shadid, Mohammad; Search for: Badawi, Mohamed; Search for: Abulrob, Abedelnasser1 |
|---|
| Affiliation | - National Research Council Canada. Human Health Therapeutics
|
|---|
| Funder | Search for: Sarepta Therapeutics Inc |
|---|
| Format | Text, Article |
|---|
| Subject | absorption; distribution; metabolism; excretion; antisense oligonucleotides; phosphorothioate; phosphorodiamidate morpholino oligomer; peptide-conjugated phosphorodiamidate morpholino oligomers |
|---|
| Abstract | Antisense oligonucleotides (ASOs) have emerged as a promising novel drug modality that aims to address unmet medical needs. A record of six ASO drugs have been approved since 2016, and more candidates are in clinical development. ASOs are the most advanced class within the RNA-based therapeutics field. |
|---|
| Publication date | 2021-11-02 |
|---|
| Publisher | Taylor & Francis |
|---|
| Licence | |
|---|
| In | |
|---|
| Language | English |
|---|
| Peer reviewed | Yes |
|---|
| Export citation | Export as RIS |
|---|
| Report a correction | Report a correction (opens in a new tab) |
|---|
| Record identifier | fc78cb22-41a7-467c-a740-a20f5da1e7d5 |
|---|
| Record created | 2022-09-16 |
|---|
| Record modified | 2022-09-16 |
|---|
